Referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for c…
The Knock Out Cancer Act directs additional appropriations to the National Cancer Institute (NCI) for each fiscal year 2026 through 2030 equal to 25 percent of the total amount appropriated to the NCI in fiscal year 2022, with those amounts remaining available until expended and specified as supplemental to other NCI funding. The bill also requires HHS, through the FDA Commissioner, to study causes of cancer drug shortages (including economic, supply chain, development/approval delays, and lack of generics/biosimilars) and to deliver a report with recommendations to Congress within one year.
Degree of support for new federal spending: liberals and centrists are generally supportive, while conservatives worry about deficits and prefer offsets or reallocation.
Relative to its intended legislative type, this bill establishes a clear, formula-based appropriation to increase NCI funding for five years and mandates a one-year HHS/FDA study and report on cancer drug shortages.
The Knock Out Cancer Act directs additional appropriations to the National Cancer Institute (NCI) for each fiscal year 2026 through 2030 equal to 25 percent of the total amount appropriated to the NCI in fiscal year 2022, with those amounts remaining available until expended and specified as supplemental to other NCI funding.
The bill also requires HHS, through the FDA Commissioner, to study causes of cancer drug shortages (including economic, supply chain, development/approval delays, and lack of generics/biosimilars) and to deliver a report with recommendations to Congress within one year.
The bill contains findings about cancer mortality, the importance of research and early detection, and suggests substantial increases in investment may be needed.
On content alone, the bill addresses a broadly popular and noncontroversial policy area (cancer research and drug shortages), is administratively simple, and includes a time-limited funding window — all features that improve enactment prospects. The primary barrier is fiscal: it mandates multi-year additional appropriations tied to a past fiscal year amount without offsets, which creates budgetary objections and requires action by appropriations leaders. Passage likelihood improves if the measure is folded into larger appropriations or an omnibus vehicle or paired with offsets, but as a stand-alone appropriation measure its path is moderately challenging.
Relative to its intended legislative type, this bill establishes a clear, formula-based appropriation to increase NCI funding for five years and mandates a one-year HHS/FDA study and report on cancer drug shortages. The bill is specific about the funding formula and the reporting deadline but provides limited fiscal detail, little guidance on internal use of funds, and minimal ongoing accountability or performance measurement tied to the appropriation.
Degree of support for new federal spending: liberals and centrists are generally supportive, while conservatives worry about deficits and prefer offsets or reallocation.
These are examples from the analysis, not a ranked list of the most-affected groups.
Degree of support for new federal spending: liberals and centrists are generally supportive, while conservatives worry about deficits and prefer offsets or reallocation.
A mainstream liberal would likely welcome the bill’s stated goal of increasing cancer research funding and its required study of drug shortages, seeing both as concrete steps to reduce mortality and improve patient outcomes.
They would note the positive signal of consistent supplemental funding for the NCI and the potential to accelerate treatments, diagnostics, and equity-focused research.
At the same time, they may view the prescribed amount (25% of FY2022 each year) as possibly insufficient relative to needs, want clearer direction that funds target disparities, prevention, and access, and may be concerned the bill does not address drug pricing or guarantee equitable distribution of benefits.
A centrist/moderate would generally view the bill favorably as a targeted, bipartisan-seeming effort to bolster cancer research and to have the FDA study drug shortages, but would have pragmatic concerns about fiscal discipline, oversight, and measurable results.
They would appreciate the multi-year commitment and the study mandate, while wanting clear accountability, performance metrics, and assessment of whether this approach is the most cost-effective way to reduce mortality.
They would likely support the bill conditionally if accompanied by transparency and efficiency safeguards.
A mainstream conservative would view the bill as addressing a non-ideological public health problem but would be concerned about new mandatory spending without offsets and expanded federal control over research priorities.
They may support the FDA study of drug shortages as a useful diagnostic, but express skepticism that additional federal appropriations are the most efficient solution versus private-sector incentives or regulatory reform.
Overall, they would be cautiously skeptical and likely seek fiscal or structural changes before supporting it.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill addresses a broadly popular and noncontroversial policy area (cancer research and drug shortages), is administratively simple, and includes a time-limited funding window — all features that improve enactment prospects. The primary barrier is fiscal: it mandates multi-year additional appropriations tied to a past fiscal year amount without offsets, which creates budgetary objections and requires action by appropriations leaders. Passage likelihood improves if the measure is folded into larger appropriations or an omnibus vehicle or paired with offsets, but as a stand-alone appropriation measure its path is moderately challenging.
The bill has not accumulated any surfaced votes yet.
Degree of support for new federal spending: liberals and centrists are generally supportive, while conservatives worry about deficits and p…
On content alone, the bill addresses a broadly popular and noncontroversial policy area (cancer research and drug shortages), is administra…
Relative to its intended legislative type, this bill establishes a clear, formula-based appropriation to increase NCI funding for five years and mandates a one-year HHS/FDA study and report on cancer drug shortages. The…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.